Debido a labores de actualización y migración del repositorio a una versión más reciente, el sistema permanecerá disponible únicamente para consulta hasta nuevo aviso. Agradecemos su comprensión.
Compartir
Título
Chronic sarpogrelate treatment improves renal sympathetic hyperactivity in experimental diabetes.
Autor(es)
Palabras clave
5-HT modulation
diabetes
nephropathy
sarpogrelate
sympathetic neurotransmission
sympatholytic effect
Clasificación UNESCO
3209 Farmacología
Fecha de publicación
2024-07
Editor
Elsevier
Citación
Fernández-González, J. F., García-Pedraza, J. Á., Terol-Úbeda, A. C., Martín, M. L., Morán, A., & García-Domingo, M. (2024). Chronic sarpogrelate treatment improves renal sympathetic hyperactivity in experimental diabetes. Biomedicine & Pharmacotherapy, 176, 116814.https://doi.org/10.1016/j.biopha.2024.116814
Resumen
[EN]Diabetes and derived complications, especially diabetic nephropathy and neuropathy annually cause great morbimortality worldwide. 5-hydroxytryptamine (5-HT) acts as a modulator of renal sympathetic input and vascular tone. In this line, 5-HT2 receptor blockade has been linked with reduced incidence and progression of diabetic microvascular alterations. In this work, we aimed to determine, in diabetic rats, whether 5-HT2 blockade ameliorates renal function and to characterize the serotonergic modulatory action on renal sympathetic neurotransmission. Diabetes was induced in male Wistar rats by alloxan administration (150 mg/kg, s.c.), and sarpogrelate (30 mg/kg·day, p.o.; 5-HT2 antagonist) was administered for 14 days (DM-S). Normoglycemic and diabetic (DM) animals were maintained as aged-matched controls. At 28th day, DM-S animals were anesthetized and prepared for the in situ autoperfusion of the kidney. Renal vasoconstrictor responses were induced electrically or by i.a. noradrenaline (NA) administration. The role of 5-HT and selective 5-HT agonist/antagonist were studied on these renal vasopressor responses. Sarpogrelate treatment decreased renal sympathetic-induced vasopressor responses, reduced renal hypertrophy and kidney damage markers increased in DM. Intraarterial 5-HT inhibited the sympathetic-induced renal vasoconstrictions, effect reproduced by 5-CT, AS-19, L-694,247 and LY 344864 (5-HT1/5/7, 5-HT7, 5-HT1D and 5-HT1F receptor agonists, respectively). Blocking 5-HT1D/1F/7 receptors completely abolished the 5-CT sympatho-inhibition. NA vasoconstrictions were not altered by any of the 5-HT agonists tested. Thus, in experimental diabetes, chronic sarpogrelate treatment reduces renal damage markers, kidney hypertrophy and renal sympathetic hyperactivity and modifies serotonergic modulation of renal sympathetic neurotransmission, causing a sympatho-inhibition by prejunctional 5-HT1D/1F and 5-HT7 activation.
URI
ISSN
0753-3322
DOI
10.1016/j.biopha.2024.116814
Versión del editor
Aparece en las colecciones
Ficheros en el ítem
Tamaño:
841.2Kb
Formato:
Adobe PDF
Descripción:
Articulo publicado













